Safety Profile of Gutless Adenovirus Vectors Delivered into the Normal Brain Parenchyma: Implications for a Glioma Phase 1 Clinical Trial

Adenoviral vectors (Ads) have been evaluated in clinical trials for glioma. However, systemic immunity against the vectors can hamper therapeutic efficacy. We demonstrated that combined immunostimulation and cytotoxic gene therapy provides long-term survival in preclinical glioma models. Because hel...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ghulam Muhammad, A.K.M., Xiong, Weidong, Puntel, Mariana, Farrokhi, Catherine, Kroeger, Kurt M., Salem, Alireza, Lacayo, Liliana, Pechnick, Robert N., Kelson, Kyle R., Palmer, Donna, Ng, Philip, Liu, Chunyan, Lowenstein, Pedro R., Castro, Maria G.
Format: Artigo
Langue:Inglês
Publié: Mary Ann Liebert, Inc. 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3545520/
https://ncbi.nlm.nih.gov/pubmed/22950971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hgtb.2012.060
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires